Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 1/2 1

Status

Recruiting 5Completed 4Not yet recruiting 2Active not recruiting 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Conditions

Breast Neoplasms 1223Neoplasms 1028Carcinoma, Non-Small-Cell Lung 747Prostatic Neoplasms 693Colorectal Neoplasms 591Lung Neoplasms 576Leukemia, Myeloid, Acute 396Pancreatic Neoplasms 395Neoplasm Metastasis 389Ovarian Neoplasms 369Multiple Myeloma 369Stomach Neoplasms 318Carcinoma, Hepatocellular 303Melanoma 283Brain Neoplasms 281Recurrence 274Squamous Cell Carcinoma of Head and Neck 266Head and Neck Neoplasms 239Glioblastoma 235Endometrial Neoplasms 232Triple Negative Breast Neoplasms 230Lymphoma 223Precursor Cell Lymphoblastic Leukemia-Lymphoma 222Uterine Cervical Neoplasms 221Sarcoma 202Hematologic Neoplasms 202Urinary Bladder Neoplasms 198Esophageal Neoplasms 190Carcinoma, Renal Cell 188Lymphoma, Non-Hodgkin 176

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Advanced Malignant Tumors × 1 year × Clear all
NCT07038005 2026-02-09

A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors

Shenyang Sunshine Pharmaceutical Co., LTD.

Phase 1 Recruiting
96 enrolled

Advanced Malignant Tumors

NCT06877650 2026-01-29

First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors

Shanghai JMT-Bio Inc.

Phase 1/2 Recruiting
436 enrolled

Advanced Malignant Tumors

NCT07016490 2026-01-28

A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors

Shenyang Sunshine Pharmaceutical Co., LTD.

Phase 1 Recruiting
15 enrolled

Advanced Malignant Tumors

NCT07043751 2026-01-21

A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Recruiting
216 enrolled

Advanced Malignant Tumors

NCT07032298 2025-07-25

A Phase I Study of SSGJ-612 in Patients With Advanced Solid Tumors

Shenyang Sunshine Pharmaceutical Co., LTD.

Phase 1 Recruiting
30 enrolled

Advanced Malignant Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡